CD34− Orbital Fibroblasts from Patients with Thyroid-Associated Ophthalmopathy Modulate TNF-α Expression in CD34+ Fibroblasts and Fibrocytes

Yan Lu,Stephen J. Atkins,Roshini Fernando,Aaron Trierweiler,Tunde Mester,Ana Beatriz Diniz Grisolia,Pei Mou,Priscila Novaes,Terry J. Smith
DOI: https://doi.org/10.1167/iovs.18-23951
2018-01-01
Abstract:PURPOSE. Orbital fibroblasts from patients with Graves' disease (GD-OF) express many different cytokines when treated with bovine thyrotropin (bTSH). The present study aimed to determine why TNF-alpha cannot be induced by bTSH in GD-OF. METHODS. Fibrocytes and GD-OFs were cultivated from donors who were patients in a busy academic medical center practice. Real-time PCR, Western blot analysis, reporter gene assays, cell transfections, mRNA stability assays, ELISA, and flow cytometry were performed. RESULTS. We found that bTSH induces TNF-alpha dramatically in fibrocytes but is undetectable in GD-OF. The induction in fibrocytes is a consequence of increased TNF-alpha gene promoter activity and is independent of ongoing protein synthesis. It could be attenuated by dexamethasone and the IGF-1 receptor inhibiting antibody, teprotumumab. When separated into pure CD34(+) OF and CD34(-) OF subsets, TNF-alpha mRNA became highly inducible by bTSH in CD34(+) OF but remained undetectable in CD34(-) OF. Conditioned medium from CD34(-) OF inhibited induction of TNF-alpha in fibrocytes. CONCLUSIONS. Our data indicate that CD34(-) OF appear to release a soluble(s) factor that downregulates expression and induction by bTSH of TNF-alpha in fibrocytes and their derivative CD34(+) OF. We proffer that CD34(-) OF produce an unidentified modulatory factor that attenuates TNF-alpha expression in GD-OF and may do so in the TAO orbit.
What problem does this paper attempt to address?